{
    "root": "7c7ee150-e4f6-4951-b2fb-7460f6898d39",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clozapine",
    "value": "20250210",
    "ingredients": [
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "clozapine tablets atypical antipsychotic indicated : \u2022 treatment-resistant schizophrenia . efficacy established active-controlled study . ( 1.1 , 14.1 ) \u2022 reducing suicidal behavior patients schizophrenia schizoaffective disorder . efficacy established active-controlled study . ( 1.2 , 14.2 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 starting dose : 12.5 mg daily twice daily . ( 2.2 ) \u2022 cautious titration divided schedule . ( 2.2 , 5.3 ) \u2022 titration : increase total daily increments 25 mg 50 mg per day , well-tolerated . ( 2.2 ) \u2022 target dose : 300 mg 450 mg per day , divided doses , end 2 weeks . ( 2.2 ) \u2022 subsequent increases : increase increments 100 mg less , twice weekly . ( 2.2 ) \u2022 maximum daily dose : 900 mg ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "clozapine tablets contraindicated patients history serious hypersensitivity clozapine ( e.g . , photosensitivity , vasculitis , erythema multiforme , stevens-johnson syndrome ) component clozapine tablets [ ( 6.2 ) ] .",
    "indications_original": "Clozapine tablets are an atypical antipsychotic indicated for: \u2022 Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) \u2022 Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 )",
    "contraindications_original": "\u2022 Starting Dose: 12.5 mg once daily or twice daily. ( 2.2 ) \u2022 Use cautious titration and divided dosage schedule. ( 2.2 , 5.3 ) \u2022 Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated. ( 2.2 ) \u2022 Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. ( 2.2 ) \u2022 Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. ( 2.2 ) \u2022 Maximum daily dose: 900 mg ( 2.2 )",
    "adverseReactions_original": "Clozapine tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine tablets [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Clozapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        }
    ]
}